BOSTON, Aug. 17, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present a summary of data highlighting the broad potential applications for the company’s Vaxfectin® adjuvant at the Third Annual Novel Vaccines: Adjuvants & Delivery Systems Conference, (Boston – August 16-18).
